2I4
3alpha-[(3-carboxy-3-methylbutanoyl)oxy]-8alpha,9beta,10alpha,13alpha,17alpha,19beta-lup-20(29)-en-28-oic acid
Find entries where: 2I4
is present as a standalone ligand in 3 entries
Chemical Component Summary | |
---|---|
Name | 3alpha-[(3-carboxy-3-methylbutanoyl)oxy]-8alpha,9beta,10alpha,13alpha,17alpha,19beta-lup-20(29)-en-28-oic acid |
Synonyms | Bevirimat |
Identifiers | (1~{R},3~{a}~{S},5~{a}~{R},5~{b}~{R},7~{a}~{R},9~{S},11~{a}~{R},11~{b}~{R},13~{a}~{R},13~{b}~{R})-9-(3,3-dimethyl-4-oxidanyl-4-oxidanylidene-butanoyl)oxy-5~{a},5~{b},8,8,11~{a}-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7~{a},9,10,11,11~{b},12,13,13~{a},13~{b}-hexadecahydrocyclopenta[a]chrysene-3~{a}-carboxylic acid |
Formula | C36 H56 O6 |
Molecular Weight | 584.826 |
Type | NON-POLYMER |
Isomeric SMILES | CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)CC(C)(C)C(=O)O)C)C(=O)O |
InChI | InChI=1S/C36H56O6/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41)/t22-,23+,24-,25+,26-,28+,33-,34+,35+,36-/m0/s1 |
InChIKey | YJEJKUQEXFSVCJ-WRFMNRASSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 98 |
Chiral Atom Count | 10 |
Bond Count | 102 |
Aromatic Bond Count | 0 |
Drug Info: DrugBank
DrugBank ID | DB06581 |
---|---|
Name | Bevirimat |
Groups | investigational |
Description | Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. This compound belongs to the androgens and derivatives, which are hydroxylated C19 steroid hormones. They are known to favour the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. Bevirimat targets the protein gag-pol polyprotein. Bevirimat is derived from a betulinic acid-like compound, first isolated from <i>Syzygium claviflorum</i>, a Chinese herb. It is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos. |
Synonyms | Bevirimat |
Indication | Investigated for use/treatment in HIV infection. |
Categories |
|
CAS number | 174022-42-5 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Gag-Pol polyprotein | MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGL... | unknown |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
PubChem | 457928 |
ChEMBL | CHEMBL404519 |
ChEBI | CHEBI:65484 |